meta-analysis. This will be important work. I look forward to the results and have no major problems with the planned statistical analysis, even though I do not completely understand the need to pre-publish the protocol of a meta-analysis (such a step is, in my opinion, suitable for original research, notably ongoing trials).
Some specific comments and suggestions: 1) Page 5 of PDF document (4 of the manuscript), line 130: It is NOT true that guidelines state that ALL provoked VTE patients SHOULD receive AT indefinitely. In both the ACCP and the ESC Guidelines, the statement is much more differentiated. Please cite the correct recommendations of both guidelines.
2) Page 6 of PDF document (5 of manuscript), line 138: The factor "Bleeding under anticoagulation" must be explicitly mentioned here. Please also see my last comment on the limitations of the study.
3) Page 7, line 187: Using the terminology of "strong provoking factor" for cancer is formally misleading. Besides, there are several types of "cancer-associated VTE": active cancer, cancer diagnosed after VTE, history of cancer... Do you plan to exclude all studies in which cancer was or had been present but could be cured? 4) Page 7, line 188: Please specify here already (it is partly explained on the next page) what "study setting" means. Are singlearmed prospective cohort studies included ? What about "real-world" observational studies? 5) Page 13, line 370: Will the EINSTEIN Choice study be included in this analysis? 6) Page 14, line 415: Major limitation: This meta-analysis cannot address a key aspect of the decision process regarding the duration of the anticoagulation, namely the impact of the estimated (or observed) bleeding risk under ongoing anticoagulation. Balancing between the risk of recurrence and bleeding, which is wisely and nicely highlighted in the ACCP guidelines, is the critical step, and this must be clearly mentioned to avoid falsely high expectations from a meta-analysis focusing on recurrence alone.
VERSION 1 -AUTHOR RESPONSE
Response to Reviewer 1 (TL) Comments: "This is a well written manuscript with a clear pre-specified clinical question. Follows the textbook regarding the Grade methodology."
We thank the reviewer for their positive feedback. "1. Page 6, line 182. The eligibility criteria include initial treatment with edoxaban. However, edoxaban, as with dabigatran, is not approved for use as monotherapy for VTE. Perhaps the authors should treat the edoxaban like dabigatran, adding it as a 4th option for longer term anticoagulation."
We agree with the reviewer and thank the reviewer for this comment. We have made the following change: "Eligible patients should initially be treated with either 1) rivaroxaban or apixaban; or 2) intravenous heparin/ low molecular weight heparin (LMWH) injections administered for at least 5 days followed by VKAs, dabigatran, or edoxaban." "The authors plan to include 1st episode, major, symptomatic DVT or PE, unprovoked or provoked by weak transient risk factors. Their primary outcome also includes "major" recurrent VTE. All these terms are well defined, except for "major". Please elaborate on major
We thank the reviewer for this comment, and apologize for the ambiguity regarding "major" VTE. By "major" VTE, we meant to refer to VTE that is either a proximal DVT and/or segmental or greater PE. However, as stated in our protocol, we plan to report the rate of recurrent VTE, as well as the rate of recurrent VTE further broken down in to recurrent isolated proximal DVT, isolated distal DVT, isolated PE, fatal PE, DVT+/-PE, PE+/-DVT, PE+DVT (as/if available from studies). Furthermore, we have planned a subgroup analysis of the rate of recurrent VTE based on the site of initial VTE (including isolated proximal DVT, isolated distal DVT, isolated PE, PE+/-DVT, DVT+/-PE, and PE+DVT), as/if available from studies. As such, we have now removed the term "major" to avoid any confusion/issues during data extraction.
Page 9, lines 258-271. Some of these bullet points have odd numbers of parentheses. Please correct.
We thank the reviewer for pointing this out. We have now corrected this.
Response to Reviewer 2 (SVK) Comments:
"This is the protocol of an important planned systematic review and meta-analysis. This will be important work. I look forward to the results and have no major problems with the planned statistical analysis…"
We thank the reviewer for their positive feedback. 1) Page 5 of PDF document (4 of the manuscript), line 130: It is NOT true that guidelines state that ALL provoked VTE patients SHOULD receive AT indefinitely. In both the ACCP and the ESC Guidelines, the statement is much more differentiated. Please cite the correct recommendations of both guidelines.
We agree with the reviewer and thank the reviewer for this comment. We have made the following change: "Given the seemingly high risk of recurrence after cessation of AT, current guidelines suggest that all unprovoked VTE patients, with non-high bleeding risk, should be considered for indefinite anticoagulation [Kearon et al. 2016, Chest; Konstantinides et al. 2014 , Eur Heart J]."
We agree with the reviewer and thank the reviewer for this comment. We have incorporated the following to emphasize bleeding under anticoagulation: "Hence, a high-priority question remains to be answered: which unprovoked VTE patients should continue on AT indefinitely, and which patients may safely discontinue anticoagulants after completing 3-6 months of initial therapy? As mentioned previously, although not the only important factor to consider (i.e. risk of major bleeding from continuing anticoagulation, and patient preferences), this decision predominately rests on the poorly established, long-term risk of VTE recurrence after stopping anticoagulation."
3) Page 7, line 187: Using the terminology of "strong provoking factor" for cancer is formally misleading. Besides, there are several types of "cancer-associated VTE": active cancer, cancer diagnosed after VTE, history of cancer... Do you plan to exclude all studies in which cancer was or had been present but could be cured?
We thank the reviewer for this comment, and agree that using "strong" provoking factor for cancer can be misleading. As such, we have changed the word "strong" to "persistent" as used by the 2016 ISTH guidance for categorizing patients with VTE [Kearon et al. 2016, JTH] . To clarify this point, we have made the following change, and cited the ISTH guidance: "…Studies that limited their analyses to populations with certain diseases or conditions such as VTE in critically-ill patients, or patients with VTE provoked by a major transient and/or a persistent risk factor (i.e. active cancer) will be excluded [Kearon et al. 2016 JTH] ." According to the ISTH guidance, active cancer is one that has not received potentially curative treatment; or there is evidence that treatment has not been curative; or treatment is ongoing. We thank the reviewer for this comment, as the description of "study setting" was previously missing. Study setting is different from study design (e.g. prospective vs. retrospective cohort studies), and refers to the environment in which a study was conducted (e.g. urban vs. rural center, community hospital vs. academic hospital, North America vs. Europe). To clarify this, we have added the following: "…There will be no restrictions based on the type of study setting (e.g. urban vs rural center, community hospital vs. academic hospital, North America vs. Europe).
Yes, single-armed prospective cohort studies will be included.
In general, "real-world" observational studies include heterogeneous groups of patients that are treated in many different ways. Furthermore, outcomes in "real-world" observational studies are ascertained heterogeneously which makes extraction of homogenous data difficult. As such, we will exclude "real-world" observational studies. 5) Page 13, line 370: Will the EINSTEIN Choice study be included in this analysis?
Yes, data pertaining to the ASPIRIN arm of the EINSTEIN-CHOICE study will be included in our meta-analysis. 6) Page 14, line 415: Major limitation: This meta-analysis cannot address a key aspect of the decision process regarding the duration of the anticoagulation, namely the impact of the estimated (or observed) bleeding risk under ongoing anticoagulation. Balancing between the risk of recurrence and bleeding, which is wisely and nicely highlighted in the ACCP guidelines, is the critical step, and this must be clearly mentioned to avoid falsely high expectations from a meta-analysis focusing on recurrence alone.
We agree with the reviewer and thank the reviewer for this comment. We have incorporated the following at the end of the paragraph: "Nevertheless, it is important to highlight that our study does not address the other key aspect of the decision process regarding treatment duration for this patient population, namely, the long-term risk of major bleeding under ongoing anticoagulation, which remains uncertain.
VERSION 2 -REVIEW

REVIEWER
Timothy Liem Oregon Health & Science University United States REVIEW RETURNED 14-Jul-2017
GENERAL COMMENTS
The revisions have addressed my prior questions and suggestions. I look forward to reading this in print.
REVIEWER
Stavros Konstantinides
University Medical Center Mainz, Germany REVIEW RETURNED 21-Jun-2017
GENERAL COMMENTS
My questions and comments were addressed by the authors
